Notice to Include Zika Virus Infections in Applications Submitted in Response to RFA-AI-16-001 "Immunity to Neonates and Infants (U01)"

Notice Number: NOT-AI-16-055

Key Dates
Release Date:   May 27, 2016

Related Announcements

Issued by
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Environmental Health Sciences (NIEHS)
Office of Research on Women’s Health (ORWH)


The purpose of this announcement is to inform potential applicants of a clarification regarding the Funding Opportunity Announcement (FOA) RFA-AI-16-001 titled "Immunity in Neonates and Infants" (U01). When this FOA was originally released, the effects of Zika virus infection on the developing fetus, or possible effects on neonatal/infant immunity, were not appreciated.

Applications that include studies of neonates (0-28 days), infants (29 days-1 year) or relevant animal models infected with Zika virus in utero or postnatally are responsive to this FOA. Hypothesis-based studies designed to understand the impact of Zika virus infection on the developing immune system, including characterization of immune responses to childhood vaccines post-Zika virus infection are encouraged.

Potential applicants conducting Zika virus research outside the scope of the this FOA should consult the NIAID Funding Opportunities website and the NIH Guide for Grants and Contracts


Please direct all inquiries to:

Mercy PrabhuDas, PhD, MBA
National Institute of Allergy and Infectious Diseases (NIAID)
Telephone: 240-627-3534